Changes in Care in Spanish Pediatric Emergency Departments After the First Immunization With Nirsevimab.
| Title: | Changes in Care in Spanish Pediatric Emergency Departments After the First Immunization With Nirsevimab. |
|---|---|
| Authors: | Vazquez-Lopez P; Pediatric Emergency Department, Gregorio Marañon University Hospital, Gregorio Marañon Health Research Institute, Madrid.; Rivas-Garcia A; Pediatric Emergency Department, Gregorio Marañon University Hospital, Gregorio Marañon Health Research Institute, Madrid.; Luaces-Cubells C; Pediatric Emergency Department, Sant Joan de Déu University Hospital, Barcelona.; Perez-Gonzalez E; Pediatrics Department, Virgen Macarena University Hospital, Sevilla.; Ales-Palmer ML; Pediatric Emergency Department, Virgen de las Nieves University Hospital, Granada.; Cahis-Vela N; Pediatric Emergency Department, Consorci Corporació Sanitaria Parc Tauli, Sabadell.; Lera-Carballo E; Pediatric Emergency Department, Vall d'Hebron University Hospital, Barcelona.; Solano-Navarro C; Pediatric Emergency Department, Virgen de la Arrixaca Clinic University Hospital, Murcia.; Romero-Castillo E; Pediatric Emergency Department, Puerta del Mar University Hospital, Cádiz.; Torres-Begara EP; Pediatrics Department, Virgen de Valme University Hospital.; Sanchez-Alvarez MJ; Pediatric Emergency Department, Virgen del Rocío University Hospital, Sevilla.; Benito-Fernandez J; Pediatric Emergency Department, Cruces University Hospital, Biocruces Health Research Institute, Barakaldo, Bizkaia.; Sanz-Rueda L; Pediatric Emergency Department, Río Hortega University Hospital, Valladolid.; Garcia-Herrero MA; Pediatric Emergency Department, Príncipe de Asturias University Hospital, Alcalá de Henares.; Henares-Rodriguez A; Pediatric Emergency Department, San Cecilio University Hospital, Granada.; Yañez-Mesia S; Pediatric Emergency Department, A Coruña University Hospital Complex, A Coruña.; de Francisco-Profumo A; Pediatric Emergency Department, Germans Trias i Pujol University Hospital, Badalona.; Martinez-Mejias A; Pediatric Emergency Department, Consorci Sanitari de Terrassa University Hospital, Terrassa.; May-Llanas ME; Pediatric Emergency Department, Mutua Terrassa University Hospital, Barcelona.; Mesa-Garcia S; Pediatric Emergency Department, 12 de Octubre University Hospital, Madrid.; Aranda-Mora A; Pediatric Emergency Department, Reina Sofía University Hospital, Cordoba.; Baquero-Gomez C; Pediatric Emergency Department, Juan Ramon Jimenez University Hospital, Huelva.; de la Rosa-Sanchez D; Pediatric Emergency Department, Insular Materno Infantil University Hospital Complex, Las Palmas de Gran Canaria, Gran Canaria.; de Ceano-Vivas M; Pediatric Emergency Department, La Paz University Hospital, Madrid.; de la Torre Espí M; Pediatric Emergency Department, Niño Jesus University Hospital, Madrid.; Oliva-Rodriguez-Pastor S; Pediatric Emergency Department, Regional University Hospital, Malaga.; Guerra-Diez JSL; Pediatric Emergency Department, Marques de Valdecilla University Hospital, Santander.; Pons-Morales S; Pediatric Emergency Department, Doctor Peset Hospital, Valencia.; Gomez-Carabaza A; Pediatric Emergency Department, Joan XXIII University Hospital, Tarragona.; Campos-Calleja C; Pediatric Emergency Department, Miguel Servet University Children's Hospital, Zaragoza.; Torres-Torres AR; Pediatric Emergency Department, Miguel Servet University Children's Hospital, Zaragoza. |
| Source: | Pediatric emergency care [Pediatr Emerg Care] 2025 May 01; Vol. 41 (5), pp. 365-371. Date of Electronic Publication: 2025 Feb 07. |
| Publication Type: | Journal Article; Observational Study; Multicenter Study |
| Language: | English |
| Journal Info: | Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 8507560 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1535-1815 (Electronic) Linking ISSN: 07495161 NLM ISO Abbreviation: Pediatr Emerg Care Subsets: MEDLINE |
| Imprint Name(s): | Publication: Hagerstown, MD : Lippincott Williams & Wilkins; Original Publication: Baltimore, Md. : Williams & Wilkins, [c1985- |
| MeSH Terms: | Emergency Service, Hospital*/statistics & numerical data ; Antibodies, Monoclonal, Humanized*/therapeutic use ; Antibodies, Monoclonal, Humanized*/administration & dosage ; Respiratory Syncytial Virus Infections*/prevention & control ; Bronchiolitis*/epidemiology ; Bronchiolitis*/therapy ; Bronchiolitis*/prevention & control; Spain/epidemiology ; Hospitalization/statistics & numerical data ; Humans ; Retrospective Studies ; Infant ; Female ; Male ; Registries ; Child, Preschool |
| Abstract: | Objectives: The aim of the study is to assess the changes in the pediatric care of patients seen in the Pediatric Emergency Departments (PED) during the bronchiolitis season following the introduction of immunization with a monoclonal antibody against RSV (nirsevimab).; Methods: An observational, retrospective, multicenter study was conducted, analyzing the Bronchiolitis Registry of the Spanish Society of Pediatric Emergency Medicine. This registry, containing data on bronchiolitis cases, was initiated in December 2022. A total of 30 hospitals participated, all of which are members of the Spanish Society of Pediatric Emergency Medicine. Data from a 26-day period in 2 bronchiolitis seasons (2022: preimmunization and 2023: postimmunization) were included. Variables regarding health care burden were recorded for both periods. Quantitative variables were described using mean and SD, and the Student t test was used for comparisons between the 2 periods.; Results: Twenty-five hospitals from 11 autonomous communities were included with a mean of 47,811 PED visits/year (SD: 26,675). The number of bronchiolitis cases presenting to the PED and bronchiolitis-related admissions decreased by 41.6%(95% CI: 34.9%-48.2%) and 55.4% (95% CI: 46.6%-64.2%), respectively, while admissions for RSV bronchiolitis decreased by 60.3% (95% CI: 51.9%-68.7%). Admissions to pediatric intensive care units decreased by 81.3% (95% CI: 57.9%-100%). Furthermore, the occupancy rate in the pediatric intensive care units decreased by 30% (95% CI: 22.8%-37.3%), while a reduction of 22.4% (95% CI: 13.2%-31.5%) was observed in the occupancy rate of observation units. The number of bronchiolitis cases transferred to other hospitals decreased by 73.4% (95% CI: 29.0%-100%). Finally, there was a 60.9% (95% CI: 26.5%-95.3%) reduction in the need for high-flow oxygen therapy among bronchiolitis patients.; Conclusions: After the introduction of nirsevimab, a large portion of indicators related to the burden of care associated with bronchiolitis during its epidemic season decreased significantly.; (Copyright © 2025 Wolters Kluwer Health, Inc. All rights reserved.) |
| Competing Interests: | Disclosure: The authors declare no conflict of interest. |
| References: | Ruiz-Galiana J, Cantón R, De Lucas P, et al. Respiratory syncytial virus: a new era. Rev Esp Quimioter. 2024;37:134–148.; Ramilo O, Rodríguez-Fernández R, Peeples ME, et al. Advanced live attenuated vaccines for the prevention of respiratory syncytial virus infections in young children. J Infect Dis. 2020;222:4–6.; Colosia A, Costello J, McQuarrie K, et al. Systematic literature review of the signs and symptoms of respiratory syncytial virus. Influenza Other Respir Viruses. 2023;17:e13100.; Vildenbeest JG, Billard MN, Zuurbier RP, et al. The burden of respiratory syncytial virus in healthy term-born infants in Europe: a prospective birth cohort study. Lancet Respir Med. 2023;11:341–353.; Molina MA, de Miguel B, Ruiz JA, et al. Impact of nirsevimab immunization on RSV infections attended in the pediatric emergency department: first results in a tertiary hospital in Madrid. Enferm Infecc Microbiol Clin (Engl Ed). 2024;42:367–372.; Espeleta-Fox A, García-Salido A, Vallespín-Casas A, et al. Impact of nirsevimab on admission to a Spanish pediatric intensive care unit because of RSV bronchiolitis: unicentric observational study from 2017 to 2024. Pediatr Pulmonol. 2024;59:3783–3786.; Estrella-Porter P, Blanco-Calvo C, Lameiras-Azevedo AS, et al. Effectiveness of nirsevimab introduction against respiratory syncytial virus in the Valencian Community: a preliminary assessment. Vaccine. 2024;42:126030.; Andina Martínez D, Claret Teruel G, Gijón Mediavilla M, et al. Nirsevimab and acute bronchiolitis episodes in pediatric emergency departments. Pediatrics. 2024;154:e2024066584.; Recommendations for the use of nirsevimab against respiratory syncytial virus for the 2023-2024 season. Working Group on the use of nirsevimab against respiratory syncytial virus infection from the Vaccination Program and Registry Panel. Public Health Commission of the Interterritorial Council of the National Health System. Ministry of Health, July 2023. Accessed February 12, 2024. https://www.sanidad.gob.es/areas/promocionPrevencion/vacunaciones/comoTrabajamos/sincitial.htm.; Paniagua N, Pérez E. Note from the Working Group (WG) on Respiratory Pathology of the Spanish Society of Pediatric Emergency Medicine (SEUP). Nirsevimab: a new perspective on respiratory syncytial virus (RSV). Emerg Pediatr. 2023;2:212–214.; Francisco L, Cruz-Cañete M, Pérez C, et al. Nirsevimab for the prevention of respiratory syncytial virus disease in children. Statement of the Spanish Society of Paediatric Infectious Disease (SEIP). An Pediatr. 2023;99:257–263.; Iofrío de Arce A, Álvarez García FJ, on behalf of the Advisory Committee on Vaccines of the Spanish Association of Pediatrics (CAV-AEP). Nirsevimab and other strategies for the prevention of RSV infection. An Pediatr (Barc). 2023;99:221–223.; Update on recommendations for the use of nirsevimab for the 2024-2025 season in Spain. Accessed September 25, 2024. https://www.google.es/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&ved=2ahUKEwjrzsjGneuIAxVOSaQEHe6XCrIQFnoECBQQAQ&url=https%3A%2F%2Fwww.sanidad.gob.es%2Fareas%2FpromocionPrevencion%2Fvacunaciones%2FcomoTrabajamos%2Fdocs%2FNirsevimabActualizacion.pdf&usg=AOvVaw0UEOdRndzdrra5AFNDqKFN&opi=89978449.; Ezpeleta G, Navascués A, Viguria N, et al. Effectiveness of nirsevimab immunoprophylaxis administered at birth to prevent infant hospitalisation for respiratory syncytial virus infection: a population-based cohort study. Vaccines (Basel). 2024;12:383.; Ares-Gómez S, Mallah N, Santiago-Pérez MI, et al. Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: initial results of a population-based longitudinal study. Lancet Infect Dis. 2024;24:817–828.; Coma E, Martinez-Marcos M, Hermosilla E, et al. Effectiveness of nirsevimab immunoprophylaxis against respiratory syncytial virus-related outcomes in hospital and primary care settings: a retrospective cohort study in infants in Catalonia (Spain). Arch Dis Child. 2024;109:736–741.; Gil-Prieto R, Pérez JJ, Drago G, et al. Modelling the potential clinical and economic impact of universal immunization with nirsevimab versus standard of practice for protecting all neonates and infants in their first respiratory syncytial virus season in Spain. BMC Infect Dis. 2024;24:924.; Ernst C, Bejko D, Gaasch L, et al. 2024. Impact of nirsevimab prophylaxis on paediatric respiratory syncytial virus (RSV)-related hospitalisations during the initial 2023/24 season in Luxembourg. Euro Surveill. 2024;29:2400033.; NORMAS_ESTANDARES_CALIDAD_SUP.pdf. Accessed September 12, 2024. https://seup.org/pdf_public/gt/NORMAS_ESTANDARES_CALIDAD_SUP.pdf.; Carlos III Health Institute (ISCIII). Sentinel Surveillance of Acute Respiratory Infection in Primary Care (ARIs) and in Hospitals (ARIH). Influenza, COVID-19, and other respiratory viruses. Accessed February 12, 2024. https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/Paginas/Temporada_Gripe_2023-24.aspx.; Barbas Del Buey JF, Íñigo Martínez J, Gutiérrez Rodríguez MÁ, et al. The effectiveness of nirsevimab in reducing the burden of disease due to respiratory syncytial virus (RSV) infection over time in the Madrid region (Spain): a prospective population-based cohort study. Front Public Health. 2024;12:1441786.; López-Lacort M, Muñoz-Quiles C, Mira-Iglesias A, et al. Early estimates of nirsevimab immunoprophylaxis effectiveness against hospital admission for respiratory syncytial virus lower respiratory tract infections in infants, Spain, October 2023 to January 2024. Euro Surveill. 2024;29:2400046.; Martinón -Torres F, Mirás-Carballal S, Durán-Parrondo C. Early lessons from the implementation of universal respiratory syncytial virus prophylaxis in infants with long-action monoclonal antibodies, Galicia, Spain, September and October 2023. Euro Surveill. 2023;28:2300606.; Mallah N, Ares-Gómez S, Pardo-Seco J, et al. Assessment of effectiveness and impact of universal prophylaxis with nirsevimab for prevention of hospitalizations due to respiratory syncytial virus in infants. The NIRSE-GAL study protocol. Hum Vaccin Immunother. 2024;20:2348135.; Mestre Ferrándiz J, Rivero A, Orrico-Sánchez A, et al. Evaluation of antibody-based preventive alternatives for respiratory syncytial virus: a novel multi-criteria decision analysis framework and assessment of nirsevimab in Spain. BMC Infect Dis. 2024;24:99.; Public Health Agency of Sweden. Recommendations for the prevention of RSV in children under 12 months. 2023. Accessed February 24, 2024. https://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2023/september/barn-iriskgrupper-kan-rekommenderas-nytt-forebyggande-lakemedel-mot-rs-virus.; Haute Autorité de Santé France. Nirsevimab (Beyfortus ® ) in the prevention of respiratory syncytial virus (RSV) bronchiolitis in newborns and infants. 2023. Accessed February 27, 2024. https://www.has-sante.fr/jcms/p_3461236/fr/nirsevimab-beyfortusdans-la-prevention-des-bronchiolites-a-virus-respiratoire-syncytial-vrs-chez-les-nouveau-nes-et-lesnourrissons.; Recommendations for the use of nirsevimab for the 2024-2025 season in Spain. Accessed September 12, 2024. https://www.google.es/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&ved=2ahUKEwiC_pjXnOuIAxXDRfEDHcBzAl0QFnoECBoQAQ&url=https%3A%2F%2Fwww.sanidad.gob.es%2Fareas%2FpromocionPrevencion%2Fvacunaciones%2FcomoTrabajamos%2Fdocs%2FNirsevimab.pdf&usg=AOvVaw2lTPmvu0WlHFbFNnxDcuU7&opi=89978449.; Leonie K, Dallmeyer LK, Schüz ML, et al. Epidemiology of respiratory viruses among children during the SARS-CoV-2 pandemic: a systematic review and meta-analysis. Int J Infect Dis. 2024;138:10–18.; Dagan R, Hammitt LL, Seoane Nuñez B, et al. Infants receiving a single dose of nirsevimab to prevent RSV do not have evidence of enhanced disease in their second RSV season. J Pediatric Infect Dis Soc. 2024;13:144–147. |
| Contributed Indexing: | Keywords: acute bronchiolitis; emergency departments; nirsevimab; pediatrics |
| Substance Nomenclature: | 0 (Antibodies, Monoclonal, Humanized) |
| Entry Date(s): | Date Created: 20250207 Date Completed: 20250430 Latest Revision: 20250521 |
| Update Code: | 20260130 |
| DOI: | 10.1097/PEC.0000000000003339 |
| PMID: | 39915948 |
| Database: | MEDLINE |
Journal Article; Observational Study; Multicenter Study